Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Decline in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIFGet Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 28,300 shares, a drop of 28.4% from the May 15th total of 39,500 shares. Based on an average daily volume of 138,600 shares, the short-interest ratio is presently 0.2 days.

Appili Therapeutics Stock Performance

Shares of Appili Therapeutics stock remained flat at $0.03 during trading on Friday. 3,000 shares of the stock traded hands, compared to its average volume of 45,874. The business’s 50-day simple moving average is $0.03 and its 200-day simple moving average is $0.03. The company has a market cap of $3.73 million, a PE ratio of -0.77 and a beta of -0.53. Appili Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.08.

About Appili Therapeutics

(Get Free Report)

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.

See Also

Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.